Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Lancet Oncol. 2016 Dec 5;18(1):42–51. doi: 10.1016/S1470-2045(16)30565-4

Table 2.

Treatment-related adverse events in 74 patients with small-cell lung cancer

Grade 1–2 Grade 3 Grade 4 Grade 5
Acute kidney injury 0 (0%) 0 (0%) 0 (0%) 1 (1%)
Alanine aminotransferase increased 2 (3%) 1 (1%) 1 (1%) 0 (0%)
Amylase increased 2 (3%) 1 (1%) 0 (0%) 0 (0%)
Anaemia 7 (9%) 2 (3%) 0 (0%) 0 (0%)
Arthralgia 8 (11%) 1 (1%) 0 (0%) 0 (0%)
Aspartate aminotransferase increased 5 (7%) 1 (1%) 1 (1%) 0 (0%)
Asthenia 1 (1%) 1 (1%) 0 (0%) 0 (0%)
Blood alkaline phosphatase increased 3 (4%) 1 (1%) 0 (0%) 0 (0%)
Cardiac tamponade 0 (0%) 0 (0%) 1 (1%) 0 (0%)
Conjunctivitis 0 (0%) 1 (1%) 0 (0%) 0 (0%)
Decreased appetite 12 (16%) 0 (0%) 0 (0%) 0 (0%)
Dermatitis acneiform 3 (4%) 1 (1%) 0 (0%) 0 (0%)
Dyspnoea 6 (8%) 2 (3%) 0 (0%) 0 (0%)
Electrocardiogram ST segment elevation 0 (0%) 1 (1%) 0 (0%) 0 (0%)
Erythema 10 (14%) 0 (0%) 0 (0%) 0 (0%)
Erythema multiforme 5 (7%) 1 (1%) 0 (0%) 0 (0%)
Fatigue 23 (31%) 3 (4%) 0 (0%) 0 (0%)
Hypoalbuminaemia 13 (18%) 0 (0%) 0 (0%) 0 (0%)
Hypotension 1 (1%) 2 (3%) 1 (1%) 0 (0%)
Hypoxia 0 (0%) 1 (1%) 0 (0%) 0 (0%)
Infection 0 (0%) 0 (0%) 1 (1%) 0 (0%)
Lipase increased 1 (1%) 2 (3%) 3 (4%) 0 (0%)
Liver function test abnormal 0 (0%) 0 (0%) 1 (1%) 0 (0%)
Maculopapular rash 10 (14%) 2 (3%) 0 (0%) 0 (0%)
Nausea 14 (19%) 0 (0%) 0 (0%) 0 (0%)
Neutrophil count decreased 0 (0%) 1 (1%) 0 (0%) 0 (0%)
Palmar-plantar erythrodysaesthesia syndrome 1 (1%) 1 (1%) 0 (0%) 0 (0%)
Pancytopenia 0 (0%) 0 (0%) 1 (1%) 0 (0%)
Pericardial effusion 7 (9%) 0 (0%) 2 (3%) 0 (0%)
Peripheral oedema 18 (24%) 2 (3%) 0 (0%) 0 (0%)
Photophobia 0 (0%) 1 (1%) 0 (0%) 0 (0%)
Photosensitivity reaction 7 (9%) 1 (1%) 0 (0%) 0 (0%)
Platelet count decreased 2 (3%) 1 (1%) 0 (0%) 0 (0%)
Pleural effusion 17 (23%) 6 (8%) 0 (0%) 0 (0%)
Pulmonary oedema 0 (0%) 1 (1%) 0 (0%) 0 (0%)
Thrombocytopenia 4 (5%) 3 (4%) 5 (7%) 0 (0%)
Troponin increased 0 (0%) 1 (1%) 0 (0%) 0 (0%)
Tumour haemorrhage 0 (0%) 0 (0%) 0 (0%) 1 (1%)
Vomiting 10 (14%) 0 (0%) 0 (0%) 0 (0%)
White blood cell count decreased 0 (0%) 1 (1%) 0 (0%) 0 (0%)

Data are number of patients (%). The table shows grade 1–2 treatment-related adverse events in ≥10% of patients in any treatment cohort and all grade 3–5 adverse events. All-cause adverse events and serious adverse events are shown in the appendix (pp 11–25).

HHS Vulnerability Disclosure